Davunetide

Research compound

Davunetide (also known as NAP or AL-108) is a short peptide fragment derived from activity-dependent neuroprotective protein (ADNP), a protein essential for brain development and neuronal function. Its proposed mechanism centers on stabilizing microtubules — the internal scaffolding of neurons — and supporting healthy tau protein function, which made it a rational candidate for tauopathies, the family of neurodegenerative diseases marked by abnormal tau. Davunetide has an instructive clinical history. It advanced into human trials for conditions including progressive supranuclear palsy (a severe tauopathy) and cognition in schizophrenia, but the pivotal progressive supranuclear palsy trial did not show clinical benefit, cooling early enthusiasm. Interest has since re-emerged in a more targeted direction: ADNP syndrome (Helsmoortel-Van der Aa syndrome), a rare genetic disorder caused by ADNP mutations, where restoring ADNP-related signaling has a clearer biological rationale. Davunetide remains investigational and is not an approved treatment for any condition; it is not a validated nootropic, and self-experimentation is not supported by the evidence. It is included here as an educational reference on a well-studied neuroprotective peptide whose story illustrates both the promise and the difficulty of translating microtubule-stabilizing mechanisms into clinical benefit.